studi
object
patient
copd
experi
lower
airway
system
inflamm
acceler
declin
fev
evid
whether
inflamm
chang
time
associ
faster
declin
fev
patient
design
cohort
copd
patient
men
monitor
daili
median
year
interquartil
rang
iqr
recruit
median
age
year
iqr
fev
percentag
predict
fev
pred
iqr
result
studi
patient
experienc
exacerb
median
iqr
fev
declin
mlyr
fev
pred
yr
concern
inflammatori
marker
sputum
interleukin
il
rose
pgmlyr
sputum
neutrophil
count
rose
cell
per
gram
sputum
per
year
plasma
fibrinogen
rose
glyr
p
patient
frequent
exacerb
faster
rise
time
plasma
fibrinogen
sputum
glyr
p
n
pgmlyr
p
n
respect
compar
patient
infrequ
exacerb
use
earliest
stabl
nonexacerb
measur
marker
patient
whose
exceed
group
median
faster
fev
pred
declin
yr
p
similarli
high
neutrophil
count
fibrinogen
associ
faster
fev
pred
declin
yr
p
yr
p
respect
conclus
copd
airway
system
inflammatori
marker
increas
time
high
level
marker
associ
faster
declin
lung
function
abbrevi
bmi
bodi
mass
index
ci
confid
interv
fev
pred
fev
percentag
predict
il
interleukin
iqr
interquartil
rang
c
opd
major
caus
morbid
disabl
unit
state
unit
kingdom
project
thirdlead
caus
death
worldwid
fev
easili
measur
strongest
spirometr
predictor
mortal
patient
copd
factor
affect
declin
fev
therefor
prognost
import
copd
longterm
studi
fev
declin
shown
import
cigarett
smoke
exacerb
frequenc
factor
affect
fev
declin
copd
associ
airway
system
inflamm
although
littl
inform
inflamm
chang
time
inflamm
relat
fev
declin
airway
inflammatori
marker
higher
sever
diseas
increas
copd
exacerb
crosssect
studi
shown
system
inflammatori
marker
acutephas
reactant
plasma
fibrinogen
also
increas
copd
patient
stabl
exacerb
understand
relationship
cours
inflammatori
marker
copd
import
fev
often
littl
affect
copd
intervent
marker
may
use
assess
effect
novel
therapi
airway
patient
copd
often
bacteria
colon
recogn
higher
airway
bacteri
load
associ
increas
airway
inflamm
exacerb
also
shown
studi
rise
lower
airway
bacteri
load
stabl
copd
relat
faster
lung
function
declin
thu
possibl
bacteria
may
modul
either
airway
system
inflamm
affect
diseas
progress
copd
longitudin
studi
describ
first
time
relationship
airway
system
inflammatori
marker
fev
declin
copd
prolong
period
followup
wellcharacter
patient
cohort
monitor
patient
moderatetosever
copd
median
year
interquartil
rang
iqr
measur
fev
everi
month
hypothes
faster
declin
fev
copd
would
relat
lower
airway
system
inflamm
presenc
bacteria
detect
stabl
copd
studi
patient
recruit
east
london
copd
studi
sinc
octob
record
daili
data
year
prior
januari
select
recruit
monitor
patient
previous
describ
inevit
long
cohort
studi
patient
bacteri
inflammatori
marker
data
subject
previou
public
howev
current
analysi
interpret
complet
novel
copd
defin
fev
predict
age
height
sex
agonist
revers
andor
ml
fev
fvc
patient
signific
respiratori
diseas
copd
inabl
complet
diari
card
exclud
recruit
measur
made
height
weight
bodi
mass
index
bmi
calcul
measur
also
made
fev
fvc
peak
expiratori
flow
routin
calibr
roll
seal
spiromet
sensormed
yorba
linda
ca
revers
g
inhal
salbutamol
arteri
earlob
blood
gase
model
blood
ga
analyz
cibacorn
medfield
histori
taken
smoke
habit
year
smoke
current
smoke
statu
patient
ask
chronic
symptom
dyspnea
sputum
product
wheez
cough
defin
occur
either
day
everi
morn
stabl
exacerb
free
also
ask
longterm
inhal
oral
steroid
use
histori
cardiovascular
comorbid
note
studi
ethic
approv
ethic
committe
east
london
citi
health
author
patient
provid
written
inform
consent
patient
ask
record
diari
card
morn
increas
normal
stabl
condit
follow
dyspnea
sputum
purul
sputum
volum
major
symptom
cold
nasal
dischargecongest
wheez
sore
throat
cough
fever
minor
symptom
exacerb
onset
identifi
first
consecut
day
increas
either
two
major
symptom
one
major
symptom
plu
minor
symptom
symptom
record
continu
period
preced
onset
disregard
diagnost
process
exclud
occasion
fals
exacerb
patient
reeduc
report
presenc
rather
increas
symptom
exacerb
diari
card
symptom
record
patient
identifi
hospit
admiss
note
acut
exacerb
copd
question
patient
treatment
gener
practition
clinic
visit
patient
deterior
symptom
encourag
contact
clinic
team
dedic
man
telephon
line
approxim
exacerb
seen
clinic
gener
within
h
time
lung
function
measur
prior
treatment
exacerb
treat
antibiot
andor
steroid
depend
presenc
increas
sputum
volum
purul
sever
assess
clinic
team
patient
also
ask
attend
clinic
visit
everi
month
time
fev
measur
per
year
octob
patient
ask
smoke
habit
daili
symptom
dyspnea
sputum
purul
wheez
cough
height
weight
measur
patient
given
smoke
prior
recruit
design
exsmok
patient
recruit
smoke
continu
intermitt
consid
smoker
clinic
visit
whether
exacerb
blood
sputum
obtain
test
describ
studi
start
octob
took
year
patient
monitor
year
year
shortest
period
monitor
year
longest
year
differ
time
studi
period
exacerb
nonexacerb
visit
sputum
collect
bacteria
airway
cytokin
interleukin
il
cell
count
blood
plasma
fibrinogen
estim
figur
show
sputum
sampl
obtain
interv
throughout
studi
neutrophil
count
record
year
fibrinogen
sampl
collect
around
year
year
shown
figur
patient
two
stabl
sputum
determin
interven
time
short
reliabl
estim
longitudin
chang
method
use
fibrinogen
collect
storag
process
describ
clauss
standard
calibr
intern
standard
fibrinogen
spontan
sputum
sampl
obtain
patient
case
possibl
inducedsputum
sampl
obtain
accord
previou
methodolog
previous
shown
cell
count
inflammatori
cytokin
similar
spontan
induc
sputum
spontan
induc
sampl
avail
spontan
sampl
use
sputum
sampl
process
storag
within
h
collect
previous
describ
sputum
cytokin
assay
measur
supernat
use
quantit
enzymelink
sandwich
immunoassay
r
system
europ
abingdon
oxon
uk
express
picogram
per
millilit
supernat
repres
dilut
weight
sputum
sampl
previous
publish
quantit
identif
bacteria
sputum
sampl
process
method
previous
describ
total
lower
airway
bacteri
load
express
log
unit
use
indic
bacteri
colon
total
bacteri
load
logarithm
transform
shown
affect
chang
fev
year
paramet
copd
sever
statist
analysi
baselin
data
patient
characterist
record
recruit
present
median
iqr
annual
exacerb
frequenc
calcul
divid
total
number
exacerb
per
patient
number
day
patient
record
data
multipli
exacerb
nonexacerb
period
defin
publish
data
time
cours
inflammatori
chang
copd
exacerb
say
inflammatori
chang
resolv
purpos
analysi
read
sampl
obtain
within
period
day
day
onset
exacerb
consid
exacerb
sampl
outsid
period
nonexacerb
stabl
sampl
period
chosen
knowledg
symptom
lung
function
recoveri
phase
exacerb
overwhelm
major
exacerb
back
preexacerb
level
plot
mean
inflammatori
marker
level
day
exacerb
onset
shown
also
support
use
period
three
day
onset
use
pulmonari
symptom
due
infect
rhinovirus
coronavirus
respiratori
syncyti
virus
start
day
infect
suggest
inflammatori
process
could
start
symptomat
onset
exacerb
longitudin
chang
biomark
studi
period
assess
longitudin
chang
inflamm
infect
paramet
time
longitudin
chang
regress
model
repeatedmeasur
data
assum
random
effect
individu
use
gener
linear
mix
model
gener
estim
equat
model
procedur
stata
corpor
colleg
station
tx
procedur
design
panel
cohort
data
particularli
use
data
correl
repeatedmeasur
design
complex
error
structur
gener
linear
mix
model
use
throughout
except
cytokin
data
poissonshap
distribut
allow
chronic
symptom
binomi
distribut
allow
paramet
depend
variabl
regress
two
independ
variabl
one
time
sampl
start
studi
binari
variabl
whether
depend
variabl
measur
exacerb
analyz
effect
inflammatori
infect
marker
fibrinogen
cell
count
chronic
symptom
airway
bacteri
load
patient
characterist
smoke
gender
bmi
start
fev
declin
lung
function
use
panel
regress
procedur
describ
fev
percentag
predict
fev
pred
measur
start
studi
everi
month
predict
fev
use
record
recruit
calcul
age
sex
height
patient
longitudin
analysi
includ
independ
variabl
time
whether
fev
pred
measur
exacerb
two
four
independ
variabl
third
variabl
whether
paramet
measur
continu
scale
less
greater
equal
cohort
median
whether
patient
male
femal
whether
smoke
chronic
symptom
fourth
independ
variabl
interact
term
obtain
product
first
third
variabl
interact
term
allow
us
test
whether
fev
pred
declin
faster
group
greater
inflamm
pathogen
presenc
particular
characterist
split
cohort
use
median
creat
group
equal
size
thu
avoid
bia
need
establish
normal
clinic
accept
level
biomark
use
earliest
stabl
nonexacerb
measur
recruit
characterist
dichotom
patient
two
group
therefor
much
possibl
prospect
examin
effect
paramet
fev
pred
declin
find
substanti
chang
averag
valu
stabl
sampl
collect
throughout
studi
use
dichotom
patient
two
group
factor
tabl
smoke
gender
start
fev
pred
signific
relationship
fev
pred
declin
accordingli
analysi
perform
interact
time
covari
regress
model
thu
abl
assess
whether
fev
pred
declin
associ
marker
inflamm
independ
effect
smoke
gender
start
fev
pred
ident
approach
describ
use
assess
effect
exacerb
frequenc
dichotom
cohort
frequent
infrequ
exacerb
ie
exacerb
per
year
respect
longitudin
chang
biomark
similarli
cohort
divid
two
group
accord
whether
patient
annual
rate
chang
inflammatori
marker
less
slow
greater
fast
cohort
median
patient
men
studi
moderatetosever
copd
tabl
patient
receiv
inhal
steroid
daili
recruit
increas
patient
end
studi
thirteen
patient
receiv
oral
steroid
begin
studi
end
studi
patient
receiv
mean
sd
dosag
mgd
oral
prednisolon
end
first
year
octob
cohort
patient
recruit
subsequ
year
followup
patient
die
withdrew
voluntarili
patient
replac
maintain
approxim
patient
studi
given
time
studi
total
exacerb
median
number
exacerb
per
patient
per
year
iqr
seven
patient
exacerb
studi
period
ninetytwo
patient
nonsmok
prior
recruit
quit
studi
intermitt
quitter
continu
smoke
smoker
tabl
show
independ
effect
time
exacerb
lung
function
variou
biomark
annual
chang
fev
pred
declin
yr
equival
fev
declin
mlyr
similar
magnitud
fall
fev
pred
exacerb
plasma
fibrinogen
increas
glyr
smaller
chang
gl
rise
exacerb
sputum
increas
pgmlyr
less
pgml
rise
exacerb
airway
bacteri
load
chang
time
increas
significantli
exacerb
absolut
sputum
neutrophil
count
increas
markedli
cell
per
gram
sputum
per
year
p
smaller
cell
per
gram
sputum
rise
exacerb
eosinophil
macrophag
count
chang
time
exacerb
odd
ratio
patient
report
chronic
symptom
dyspnea
increas
year
next
confid
interv
ci
p
chang
chronic
symptom
cough
wheez
sputum
p
case
tabl
show
median
valu
first
initi
marker
inflamm
measur
studi
plasma
fibrinogen
level
relat
sputum
p
n
sputum
p
n
airway
bacteri
load
p
n
neutrophil
p
n
inflammatori
marker
relat
except
p
n
relationship
sputum
bacteri
load
fail
reach
statist
signific
p
n
analysi
fibrinogen
total
bacteria
neutrophil
count
respect
confound
gender
smoke
start
fev
pred
reveal
two
signific
p
relationship
fibrinogen
sex
p
wilcoxon
men
median
gdl
women
median
gdl
neutrophil
count
start
fev
pred
p
patient
high
inflammatori
marker
group
tabl
biomark
data
refer
sampl
collect
stabl
diseas
exacerb
free
neutrophil
count
per
gram
sputum
eosinophil
count
per
gram
sputum
log
log
total
airway
lower
airway
bacteri
load
greater
preval
heart
diseas
defin
histori
one
ischem
heart
diseas
angina
myocardi
infarct
hypertens
atrial
fibril
left
ventricular
failur
correspond
low
inflammatori
marker
group
tabl
show
effect
physic
relat
factor
tabl
fev
pred
declin
women
smoker
patient
high
start
fev
pred
faster
fev
pred
declin
p
tendenc
patient
lower
bmi
faster
declin
reach
statist
signific
p
tabl
show
effect
variou
biomark
assess
lung
function
declin
adjust
smoke
gender
high
start
fev
pred
patient
higher
plasma
fibrinogen
level
yr
faster
declin
fev
pred
yr
declin
patient
group
low
fibrinogen
level
p
differ
high
low
plasma
fibrinogen
group
fev
pred
time
zero
p
tabl
also
show
high
airway
bacteri
load
high
sputum
high
sputum
neutrophil
eosinophil
count
associ
faster
declin
fev
pred
yr
p
case
high
macrophag
lymphocyt
count
influenc
rate
lung
function
declin
p
valu
respect
figur
depict
declin
fev
pred
group
patient
high
low
fibrinogen
without
adjust
smoke
gender
start
fev
pred
patient
classifi
infrequ
frequent
exacerb
group
median
annual
exacerb
frequenc
figur
show
patient
frequent
exacerb
faster
rise
time
plasma
fibrinogen
glyr
p
n
patient
frequent
exacerb
also
faster
rise
sputum
pgmlyr
p
n
compar
rise
infrequ
exacerb
relationship
paramet
tabl
signific
patient
least
two
stabl
fibrinogen
read
annual
rate
rise
plasma
fibrinogen
could
calcul
patient
found
classifi
patient
two
equals
group
accord
annual
rate
chang
patient
higher
rate
rise
plasma
fibrinogen
rapid
declin
fev
pred
yr
p
addit
faster
declin
yr
p
could
attribut
whether
high
low
initi
fibrinogen
independ
confound
smoke
gender
initi
fev
similarli
rapid
rise
airway
bacteri
count
also
associ
fall
fev
pred
yr
n
patient
p
rapid
rate
neutrophil
count
yr
fall
n
p
patient
rapid
rise
exhibit
faster
rate
declin
fev
pred
studi
use
wellcharacter
patient
cohort
moderatetosever
copd
evalu
longitudin
chang
airway
system
inflammatori
marker
prospect
relat
level
marker
fev
declin
shown
first
time
addit
effect
smoke
gender
start
fev
pred
lung
function
declin
patient
high
index
stabl
plasma
fibrinogen
sputum
neutrophil
sputum
eosinophil
sputum
rapid
declin
time
fev
pred
also
shown
patient
persist
lower
airway
bacteri
colon
evidenc
high
lower
airway
bacteri
load
stabl
exacerb
free
also
faster
fev
pred
declin
patient
faster
rise
plasma
fibrinogen
neutrophil
count
bacteri
load
also
faster
declin
previous
shown
cohort
patient
histori
frequent
exacerb
hasten
lung
function
declin
studi
show
frequent
exacerb
faster
rise
airway
system
inflammatori
marker
first
time
result
provid
evid
increas
airway
inflamm
due
possibl
frequent
exacerb
associ
faster
lung
function
declin
patient
copd
plasma
fibrinogen
acutephas
reactant
synthes
liver
mainli
control
cytokin
secret
circul
other
previous
report
plasma
fibrinogen
elev
patient
stabl
copd
also
show
level
rise
exacerb
studi
median
plasma
fibrinogen
gl
higher
would
expect
ageand
sexmatch
control
subject
found
patient
high
plasma
fibrinogen
level
initi
stage
studi
subsequ
rapid
lung
function
declin
consist
result
previou
crosssect
studi
annual
rise
observ
studi
plasma
fibrinogen
glyr
less
rise
gl
copd
exacerb
greater
glyr
observ
crosssect
studi
normal
subject
plasma
fibrinogen
arguabl
import
risk
factor
coronari
heart
diseas
discoveri
associ
acceler
declin
lung
function
suggest
mechan
epidemiolog
proven
relationship
cardiovascular
risk
obstruct
lung
diseas
consider
interest
etiolog
system
inflammatori
respons
patient
copd
system
inflammatori
respons
associ
weight
loss
muscl
wast
characterist
sever
copd
level
system
marker
rise
exacerb
suggest
other
system
inflammatori
respons
exacerb
associ
peripher
muscl
weak
studi
unabl
show
relationship
stabl
sputum
plasma
fibrinogen
suggest
direct
link
system
airway
inflamm
agreement
previou
studi
also
show
two
compart
relat
suggest
origin
system
respons
caus
sole
releas
airway
inflammatori
mediat
system
circul
research
requir
area
studi
also
found
neutrophil
marker
airway
inflamm
rose
studi
period
relat
fev
declin
abl
show
sputum
macrophag
lymphocyt
count
relat
fev
declin
copd
eosinophil
relat
fev
declin
allow
covari
simpler
analysi
suggest
weak
confound
effect
degre
airway
inflamm
relat
sever
airway
obstruct
bronchial
inflamm
sever
patient
rise
sputum
neutrophil
time
relat
rapid
fev
declin
consist
result
previou
crosssect
studi
sputum
neutrophil
copd
sever
also
explor
relationship
copd
exacerb
frequenc
airway
system
inflamm
found
frequent
exacerb
exacerb
frequenc
exacerb
per
year
like
show
faster
rise
plasma
fibrinogen
sputum
time
patient
histori
infrequ
exacerb
two
studi
show
frequent
exacerb
rapid
declin
lung
function
thu
suggest
mechan
acut
event
contribut
chronic
deterior
fev
declin
caus
faster
rate
rise
airway
inflamm
consist
higher
sputum
level
stabl
nonexacerb
patient
histori
frequent
exacerb
compar
infrequ
exacerb
elev
system
inflammatori
respons
frequent
exacerb
suggest
group
may
particularli
prone
muscl
weak
increas
diseas
sever
thu
may
import
group
target
pulmonari
rehabilit
faster
rise
plasma
fibrinogen
frequent
exacerb
also
suggest
patient
may
group
copd
patient
risk
cardiovascular
diseas
find
extrapol
intervent
reduc
airway
inflamm
may
affect
declin
fev
copd
also
like
antiinflammatori
therapi
effect
patient
frequent
exacerb
evid
inhal
steroid
obstruct
lung
diseas
europ
studi
inhal
steroid
show
greatest
benefit
exacerb
copd
patient
higher
exacerb
frequenc
data
metaanalysi
show
probabl
inhal
steroid
small
effect
fev
declin
effect
declin
may
consequ
reduct
exacerb
also
found
patient
high
start
fev
pred
faster
declin
contrari
convent
idea
high
fev
due
slow
declin
low
fev
fast
declin
landmark
monograph
fletcher
et
al
caution
assumpt
slower
declin
group
patient
sever
copd
may
part
due
surviv
effect
faster
declin
absent
due
death
use
intens
therapi
latter
stage
diseas
lower
airway
healthi
individu
normal
steril
copd
lowerairway
bacteri
colon
occur
relat
increas
diseas
sever
copd
patient
lowerairway
bacteri
colon
increas
airway
inflammatori
marker
increas
exacerb
frequenc
studi
shown
high
load
lower
airway
bacteria
associ
rapid
fev
declin
prolong
period
extend
result
previou
shortterm
studi
also
found
airway
bacteri
load
posit
correl
sputum
abl
show
allow
confound
high
level
sputum
associ
faster
fev
pred
declin
might
reflect
small
number
avail
sampl
prevent
us
assess
chang
time
appropri
antimicrobi
therapi
reduc
airway
bacteri
load
stabl
patient
may
thu
play
import
part
reduc
airway
bacteri
load
airway
inflamm
thu
arrest
diseas
progress
copd
strength
studi
larg
data
set
regular
fev
read
consider
period
time
collect
daili
respiratori
symptom
exacerb
identifi
standard
patient
character
treatment
result
singlecent
studi
limit
studi
need
discuss
firstli
mani
patient
initi
microbi
inflammatori
marker
sampl
use
differenti
patient
high
low
group
obtain
differ
time
respect
calendar
date
time
elaps
recruit
abl
produc
suffici
sputum
analysi
use
sampl
collect
commenc
studi
seriou
drawback
primari
outcom
measureannu
declin
fev
predshould
date
sampl
assum
linear
declin
period
patient
investig
possibl
patient
transfer
low
high
group
studi
howev
bia
would
make
less
like
signific
differ
would
exist
high
low
group
secondli
data
set
incomplet
becauselik
cohort
studiesther
unavoid
dropout
found
differ
confound
inflammatori
marker
patient
die
withdrew
studi
data
shown
addit
inflammatori
marker
avail
everi
patient
prevent
us
perform
analysi
includ
one
inflammatori
marker
one
time
summari
shown
first
time
studi
high
level
airway
system
inflammatori
marker
associ
faster
subsequ
declin
fev
also
shown
inflamm
increas
time
longterm
deterior
copd
thu
futur
sever
condit
relat
inflammatori
index
presenc
chronic
airway
bacteri
colon
knowledg
relationship
biomark
diseas
progress
allow
us
design
clinic
trial
antiinflammatori
antiinfect
therapi
includ
appropri
outcom
inflammatori
marker
sinc
reflect
cours
diseas
